What is MR DNA?
MR DNA operates as a specialized provider of next-generation sequencing (NGS) and bioinformatics services, positioning itself as a critical partner for researchers focused on microbiome analysis, metagenomics, and transcriptomics. By leveraging proprietary methodologies such as the bacterial tag-encoded FLX amplicon pyrosequencing (bTEFAP), the company facilitates rapid data acquisition for complex biological studies. Beyond its core sequencing capabilities, MR DNA maintains a robust pipeline for molecular diagnostics, drawing upon over 15 years of expertise to develop novel assays that bridge the gap between raw genomic data and actionable clinical insights. Its business model emphasizes collaborative service pricing, which has effectively lowered the barrier to entry for large-scale genomic projects.
How much funding has MR DNA raised?
MR DNA has raised a total of $150K across 1 funding round:
Debt
$150K
Debt (2020): $150K with participation from PPP
Key Investors in MR DNA
PPP
Public-Private Partnership
Undisclosed Investors
Undisclosed Investors
What's next for MR DNA?
With the recent capital injection, MR DNA is well-positioned to accelerate its diagnostic assay development and expand its bioinformatics processing capacity. The strategic focus will likely shift toward enhancing the throughput of its Illumina and Ion Torrent platforms while deepening its integration into the clinical diagnostics market. By optimizing its collaborative research framework, the company aims to solidify its competitive advantage in the rapidly evolving landscape of microbial diversity studies. Future growth will be driven by the scaling of its diagnostic portfolio and the continued refinement of its high-throughput sequencing workflows, ensuring that MR DNA remains at the forefront of genomic innovation and molecular research services.
See full MR DNA company page
